Clinical Trial: Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07874490) titled 'Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC' on Oct. 08.

Brief Summary: This single-site, biomarker-enriched, randomized Phase II study will evaluate osimertinib with or without cyclosporine A (CsA) in metastatic epidermal growth factor receptor (EGFR )-mutant non-small cell lung cancer (NSCLC) [exon 19 deletion or L858R]. All consented, baseline circulating tumor DNA (ctDNA)-positive patients receive a 3-week osimertinib run-in; those with persistent ctDNA ("shedders") are randomized 1:1 to continue osimertinib or osimertinib+CsA. Plasma is collected approximately every 3 weeks in both arms for molecular r...